Market Cap 10.10B
Revenue (ttm) 39.21M
Net Income (ttm) -311.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -794.06%
Debt to Equity Ratio 0.00
Volume 640,800
Avg Vol 910,148
Day's Range N/A - N/A
Shares Out 83.15M
Stochastic %K 94%
Beta 1.95
Analysts Strong Sell
Price Target $130.56

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
JimmyOcarri
JimmyOcarri Aug. 17 at 7:58 PM
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 14 at 12:03 AM
$KYMR might actually send it
0 · Reply
MikeyNJ
MikeyNJ Aug. 6 at 2:05 PM
$KYMR Barclays increases price target from $133 to $139.
0 · Reply
forprofit12
forprofit12 Aug. 5 at 5:36 PM
$KYMR added
0 · Reply
d_risk
d_risk Aug. 5 at 2:41 PM
$KYMR - Kymera Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +256.8% above peer average (41,905 vs 11,746 across 655 peers). Kymera sharpened generic risk warnings and updated financial period data, but dropped specific disclosures on BIOSECURE Act exposure and potential cost overhang from its unused Watertown lease, modestly reducing perceived regulatory and facilities‑related risk emphasis. #Biotechnology #RegulatoryRisk #FinancialUpdates #LeaseObligations #RiskManagement 🟢 Added 🟠 Removed https://d-risk.ai/KYMR/10-Q/2026-08-05
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 2:00 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-kymera-therapeutics-inc-stock/ $KYMR Kymera Therapeutics Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 11:15 AM
$KYMR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 34.74% YoY • Reported revenue of $65M up 466.40% YoY
0 · Reply
Quantumup
Quantumup Jul. 28 at 11:10 AM
Guggenheim⬆️ $KYMR to $135 (was $125), reiterated Buy and said -- We think KYMR should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation. $GSK $AUPH NVS RHHBY Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2082060908046479485?s=20
0 · Reply
IN0V8
IN0V8 Jul. 16 at 2:55 PM
$KYMR Mizuho raises target price to $140 from $120
0 · Reply
MikeyNJ
MikeyNJ Jul. 16 at 12:17 PM
$KYMR Mizuho raises price target to $140 from $120.
0 · Reply
Latest News on KYMR
Kymera Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:30 AM EDT - 14 days ago

Kymera Therapeutics Earnings Call Transcript: Q2 2026


Kymera Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 8:30 AM EDT - 14 days ago

Kymera Therapeutics Earnings release: Q2 2026


Kymera Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 8:30 AM EDT - 14 days ago

Kymera Therapeutics Quarterly report: Q2 2026


Kymera Therapeutics Slides: Q2 2026

Aug 5, 2026, 8:30 AM EDT - 14 days ago

Kymera Therapeutics Slides: Q2 2026


Kymera Therapeutics Slides: Corporate presentation

Aug 4, 2026, 9:00 AM EDT - 15 days ago

Kymera Therapeutics Slides: Corporate presentation


Kymera Therapeutics initiated with a Hold at Deutsche Bank

2026-07-30T08:20:13.000Z - 20 days ago

Kymera Therapeutics initiated with a Hold at Deutsche Bank


Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 7 weeks ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DFTX DYN KLRA MANE MIRM


Kymera Therapeutics rises 18.6%

2026-06-25T14:05:50.000Z - 7 weeks ago

Kymera Therapeutics rises 18.6%


Kymera Therapeutics completes enrollment in BROADEN2 trial

2026-06-25T11:20:54.000Z - 7 weeks ago

Kymera Therapeutics completes enrollment in BROADEN2 trial


Kymera Therapeutics appoints Felix Baker as chairman

2026-06-24T20:11:14.000Z - 7 weeks ago

Kymera Therapeutics appoints Felix Baker as chairman


Kymera Therapeutics Appoints Felix J. Baker, Ph.D.

Jun 24, 2026, 4:01 PM EDT - 7 weeks ago

Kymera Therapeutics Appoints Felix J. Baker, Ph.D.


Kymera Therapeutics Transcript: AGM 2026

Jun 24, 2026, 8:30 AM EDT - 2 months ago

Kymera Therapeutics Transcript: AGM 2026


Kymera Therapeutics Slides: Corporate presentation

Jun 9, 2026, 7:00 AM EDT - 2 months ago

Kymera Therapeutics Slides: Corporate presentation


Kymera Therapeutics Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Kymera Therapeutics Earnings Call Transcript: Q1 2026


Kymera Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Kymera Therapeutics Earnings release: Q1 2026


Kymera Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Kymera Therapeutics Quarterly report: Q1 2026


Kymera Therapeutics Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Kymera Therapeutics Slides: Q1 2026


Kymera Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Kymera Therapeutics Proxy statement: Proxy filing


Kymera Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Kymera Therapeutics Proxy statement: Proxy filing


Kymera Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Kymera Therapeutics Earnings Call Transcript: Q4 2025


Kymera Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Kymera Therapeutics Annual report: Q4 2025


Kymera Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Kymera Therapeutics Earnings release: Q4 2025


Kymera Therapeutics Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Kymera Therapeutics Slides: Q4 2025


Kymera Therapeutics Slides: Corporate presentation

Feb 26, 2026, 7:00 AM EST - 6 months ago

Kymera Therapeutics Slides: Corporate presentation


Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 4:01 PM EST - 9 months ago

Kymera Therapeutics Announces Proposed Public Offering


This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 3:50 PM EST - 9 months ago

This Drugmaker's Stock Is Soaring Over 40% Monday


Kymera Therapeutics Transcript: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Kymera Therapeutics Transcript: Study Result


Kymera Therapeutics Press release: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Kymera Therapeutics Press release: Study Result


Kymera Therapeutics Slides: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Kymera Therapeutics Slides: Study Result


Kymera Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 1:20 PM EST - 10 months ago

Kymera Therapeutics Transcript: Stifel 2025 Healthcare Conference


Kymera Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 10 months ago

Kymera Therapeutics Slides: Corporate Presentation


Kymera Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Kymera Therapeutics Earnings Call Transcript: Q3 2025


Kymera Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Kymera Therapeutics Quarterly report: Q3 2025


Kymera Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Kymera Therapeutics Earnings release: Q3 2025


Kymera Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Kymera Therapeutics Slides: Q3 2025


Kymera Therapeutics Slides: Corporate Presentation

Nov 3, 2025, 7:00 AM EST - 10 months ago

Kymera Therapeutics Slides: Corporate Presentation


The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 1 year ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Earnings Call Transcript: Q2 2025


Kymera Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Quarterly report: Q2 2025


Kymera Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Earnings release: Q2 2025


Kymera Therapeutics Slides: Q2 2025

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Slides: Q2 2025


Kymera Therapeutics Transcript: AGM 2025

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Kymera Therapeutics Transcript: AGM 2025


Kymera Therapeutics Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Transcript: Study Result


Kymera Therapeutics Press release: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Press release: Study Result


Kymera Therapeutics Slides: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kymera Therapeutics Slides: Study Result


Kymera Therapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Earnings Call Transcript: Q1 2025


Kymera Therapeutics Quarterly report: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Quarterly report: Q1 2025


Kymera Therapeutics Earnings release: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Earnings release: Q1 2025


Kymera Therapeutics Slides: Q1 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Kymera Therapeutics Slides: Q1 2025


JimmyOcarri
JimmyOcarri Aug. 17 at 7:58 PM
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 14 at 12:03 AM
$KYMR might actually send it
0 · Reply
MikeyNJ
MikeyNJ Aug. 6 at 2:05 PM
$KYMR Barclays increases price target from $133 to $139.
0 · Reply
forprofit12
forprofit12 Aug. 5 at 5:36 PM
$KYMR added
0 · Reply
d_risk
d_risk Aug. 5 at 2:41 PM
$KYMR - Kymera Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +256.8% above peer average (41,905 vs 11,746 across 655 peers). Kymera sharpened generic risk warnings and updated financial period data, but dropped specific disclosures on BIOSECURE Act exposure and potential cost overhang from its unused Watertown lease, modestly reducing perceived regulatory and facilities‑related risk emphasis. #Biotechnology #RegulatoryRisk #FinancialUpdates #LeaseObligations #RiskManagement 🟢 Added 🟠 Removed https://d-risk.ai/KYMR/10-Q/2026-08-05
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 2:00 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-kymera-therapeutics-inc-stock/ $KYMR Kymera Therapeutics Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 11:15 AM
$KYMR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 34.74% YoY • Reported revenue of $65M up 466.40% YoY
0 · Reply
Quantumup
Quantumup Jul. 28 at 11:10 AM
Guggenheim⬆️ $KYMR to $135 (was $125), reiterated Buy and said -- We think KYMR should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation. $GSK $AUPH NVS RHHBY Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2082060908046479485?s=20
0 · Reply
IN0V8
IN0V8 Jul. 16 at 2:55 PM
$KYMR Mizuho raises target price to $140 from $120
0 · Reply
MikeyNJ
MikeyNJ Jul. 16 at 12:17 PM
$KYMR Mizuho raises price target to $140 from $120.
0 · Reply
bazza71
bazza71 Jul. 14 at 4:28 PM
$OTLK couldnt resist using a little profit to buy more $KYMR on the dip 😀 😜
0 · Reply
bazza71
bazza71 Jul. 13 at 5:24 PM
$KYMR Great opportunity to buy on the dip
0 · Reply
MooseG
MooseG Jul. 9 at 6:47 PM
$KYMR june 02 this was 71$.it has to come back down.
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Jul. 9 at 12:17 PM
$KYMR Which company are you more bullish on for AD! The Doc wants to know. Vote now!
1 · Reply
justiceforb_85
justiceforb_85 Jul. 8 at 3:34 AM
$KYMR continues to show strength.
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jul. 4 at 9:59 PM
$KYMR The previous BUY signal was issued on 06/11/2026, 21 days ago, when the stock price was 81.43. Since then, KYMR has risen by +39.40%. 75.00 to 120.18 has to reclaim 130.00 that high wick.
0 · Reply
MaverikIT
MaverikIT Jun. 30 at 1:50 PM
@Jblack500 @cynicaloptimist @No_Face_character @BustaCapital @WAJeff @IsabellaDC JB $ABVX just awesone $AXSM $NKTR $KYMR
1 · Reply
MikeyNJ
MikeyNJ Jun. 29 at 12:21 PM
$KYMR B. Riley raises price target to $155 from $117.
0 · Reply
RohR1
RohR1 Jun. 27 at 6:43 PM
$ORCL And then you have this. Top Insider Sells — Jun 26 $AVGO — Henry Samueli (Director) sold $250.0M $KYMR — Partners L P/Il Bvf (Director, See Remarks and Footnotes) sold $168.1M $ORCL — Jeffrey Henley (Director, Vice Chairman) sold $63.7M So. One of the key independent Board of Directors at ORCL sells $63 M of shares. Someone knew. In advance. And sold.
1 · Reply
MikeyNJ
MikeyNJ Jun. 26 at 3:04 PM
$KYMR Truist raises PT from $116 to $136.
0 · Reply
Quantumup
Quantumup Jun. 26 at 11:34 AM
B Riley⬆️ $KYMR-$155 and reiterated Buy CRVS APGE - $ABBV NKTR ORKA REGN $SNY GILD NRIX LLY Here's what B Riley had to say in its note to investors: https://x.com/Quantumup1/status/2070470389189267487?s=20
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 25 at 11:58 PM
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline $KYMR $VTI $VB https://stocktwits.com/news/equity/markets/kymr-stock-clocks-best-day-in-over-6-months-on-advancing-eczema-trial-timeline/cZ1GUNuR7Xr
0 · Reply